Can a patient undergo a second course of terbinafine therapy if the first course was completed without adverse reactions and liver function is normal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can a Patient Have a Second Round of Terbinafine?

Yes, a second course of terbinafine is explicitly recommended when disease persists after initial treatment, provided liver function remains normal and the patient had no adverse reactions to the first course. 1

Re-treatment Protocol

The British Association of Dermatologists guidelines clearly state that patients should be re-evaluated 3-6 months after treatment initiation and further treatment should be given if the disease persists 1. This is standard practice, not an exception.

Key Requirements Before Second Course:

  • Verify normal liver function tests - Check AST and ALT before retreatment 2
  • Confirm persistent infection - Obtain mycological confirmation (KOH prep, fungal culture, or nail biopsy) 2
  • Assess first course tolerance - Ensure no hepatotoxicity, taste/smell disturbance, or serious skin reactions occurred 1
  • Rule out active/chronic liver disease - Terbinafine is contraindicated in these patients 1

Dosing for Second Course

Use the same standard dosing as initial treatment:

  • Fingernail onychomycosis: 250 mg daily for 6 weeks
  • Toenail onychomycosis: 250 mg daily for 12-16 weeks 1

Monitoring During Retreatment

Baseline liver function tests are mandatory before starting the second course 2. The FDA label requires measurement of serum transaminases (ALT and AST) before prescribing terbinafine 2.

While routine periodic monitoring during treatment remains controversial 3, patients must be educated to immediately report symptoms of liver injury: persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools 2. If these occur, discontinue terbinafine immediately and check liver function 2.

Clinical Context

The need for retreatment is not uncommon. Long-term follow-up data shows that even after initial mycological cure, 23% of terbinafine-treated patients experienced relapse 1. This is significantly lower than itraconazole (53% relapse rate), supporting terbinafine as first-line even for retreatment 1.

Important Caveats:

  • Hepatotoxicity risk: While rare (0.04% serious adverse events), liver injury typically occurs within 4-6 weeks of treatment, with mean onset at 30 days 1, 3. Most cases are symptomatic with jaundice, abdominal pain, and malaise 3
  • Permanent taste disturbance: Warn patients this can be permanent, though very rare 1
  • Drug persistence: Terbinafine remains detectable in nails for 6 months after treatment completion, so optimal clinical effect appears months after therapy ends 1

Absolute Contraindications to Retreatment:

  • Active or chronic liver disease 1
  • Previous allergic reaction to terbinafine (risk of anaphylaxis) 2
  • Development of Stevens-Johnson syndrome or toxic epidermal necrolysis during first course 1, 2
  • Permanent taste or smell disturbance from first course 2

Bottom line: A second course is standard practice when infection persists, the patient tolerated the first course, and liver function is normal. Check baseline LFTs, educate about warning symptoms, and use the same dosing regimen as initial treatment.

References

Related Questions

Can oral terbinafine be used in a patient with mild transaminitis (ALT and AST approximately 2–3 × the upper limit of normal)?
At what point should terbinafine (an antifungal medication) be discontinued in a patient with elevated liver enzymes, particularly those with pre-existing liver conditions or taking other hepatotoxic medications?
What is the recommended schedule for monitoring liver function tests (and other labs) in a patient taking oral terbinafine, including baseline testing and follow‑up intervals, and how should this be adjusted for risk factors such as pre‑existing liver disease, heavy alcohol use, or concurrent hepatotoxic medications?
Can I take Lamisil (terbinafine) when my bilirubin is elevated?
What are the effects of oral Terbinafine (Lamisil) on the liver?
How should sodium cromoglicate be used, dosed, and monitored for prophylaxis of mild allergic asthma and allergic rhinitis?
What is the recommended treatment for pulmonary‑renal syndrome?
Which oral antibiotic is safe for a patient who has dumping syndrome and postural orthostatic tachycardia syndrome (POTS)?
When is serum uric acid testing indicated, what are the normal reference ranges, and how should abnormal results be managed?
Which antibiotics are appropriate to cover both an asthma exacerbation and a urinary tract infection in an adult patient?
What are the Salter‑Harris fracture classifications?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.